Skip to main content
OpenTrials

Clinical trial condition

Locally Advanced Solid Tumor

Explore clinical trials studying Locally Advanced Solid Tumor. Study availability and eligibility vary by location and protocol.

31 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Locally Advanced Solid Tumor trial results

Completed

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

NCT04200963

Conditions
Advanced Cancer, Advanced Solid Tumor, Bladder Cancer, +35 more
Locations
  • Banner Health- MD Anderson Cancer Center Gilbert, Arizona, United States
  • Florida Cancer Specialists - Sarasota Sarasota, Florida, United States
  • Rush University Medical Center Chicago, Illinois, United States
  • Johns Hopkins Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Completed

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT01390818

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +37 more
Locations
  • Pinnacle Oncology Hematology Scottsdale, Arizona, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425

Conditions
Advanced Solid Tumor, Cancer, Locally Advanced Solid Tumor, +7 more
Locations
  • City of Hope Duarte, California, United States
  • Ochsner Clinic Foundation New Orleans, Louisiana, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • Hadassah Medical Center Jerusalem, Israel
View Trial Details
Active, Not Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609

Conditions
2L+ Cervical Cancer, Advanced Solid Tumor, Female Urogenital Diseases, +27 more
Locations
  • Ascendis Pharma Investigational Site Los Angeles, California, United States
  • Ascendis Pharma Investigational Site Los Angeles, California, United States
  • Ascendis Pharma Investigational Site Springfield, Illinois, United States
  • Ascendis Pharma Investigational Site Louisville, Kentucky, United States
View all 68 locations
View Trial Details

Related conditions